Press "Enter" to skip to content

Breakthrough for Cancer Treatment without Side Effects

Scientists at Princeton University in the United States have published two articles explaining their promising new medicine after more than 15 years of hard work. The scientists wanted to find a “little-known but deadly” gene called metadherin (MTDF), which is found in almost all forms of cancer. Because metadherin is found in lung, colon, breast, prostate, and liver cancers, it could be a future target for cure development. Princeton researchers, according to cancer biologist Yibin Kang, have discovered a mechanism to assault or inhibit this gene. More importantly, their preliminary research suggests that this can be done without causing any visible negative Effects.

“You can’t find a better pharmacological target than this: MTDF is vital for most major human malignancies, but not for normal cells, and it can be destroyed with no noticeable side Effects,” Professor Kang added. The novel treatment has only been tried on mice and human tissue thus far. However, the researchers are certain that in a few years, they will be able to move on to clinical patient studies. Their findings were published in the journal Nature Cancer earlier this week. “In the two articles we’re releasing back-to-back today, we identify a chemical, show that it’s Effects against cancer, and show that it’s extremely successful when paired with chemotherapy and immunotherapy,” Professor Kang said.

Even though metastatic malignancies are frightening, we can tackle them and make them more treatable by understanding how they work and their reliance on important pathways like MTDF. Over the years, the expert’s research has mostly concentrated on cancer metastasis. Cancer’s ability to travel from one part of the body to another is known as metastasis, and it makes the disease considerably more likely to kill. According to data from the National Cancer Institute in the United States, 99 percent of cancer patients survive five years after being diagnosed. When cancer has spread, however, only approximately 29% of individuals survive.

Minhong Shen, the study’s principal author and associate researcher, said: In the United States, metastatic breast cancer kills over 40,000 people each year, and patients don’t respond well to traditional treatments like chemotherapies, targeted therapies, or immunotherapies. In metastatic breast cancer mouse models, our research identified a number of chemical compounds that could improve chemotherapy and immunotherapy response rates significantly. Professor Kang and colleagues claim that MTDH permits cancer tumours to withstand the stress of chemotherapy and mutes the alarm cry of organs invaded by a tumour. The novel medicine that the researchers created essentially reactivates the body’s alert system.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *